רווהכול
megapharm ltd - borneol; camphene; cineole; menthol; menthone; pinene; pinene - קפסולות - menthol 32 mg; menthone 6 mg; pinene 3.4 mg; borneol 5 mg; camphene 5 mg; cineole 2 mg; pinene 13.6 mg - an adjuvant in the treatment of gall-bladder stones and liver diseases.
תרדיפרון
padagis israel agencies ltd, israel - ferrous sulfate - טבליה - ferrous sulfate 247.25 mg - iron bivalent, oral preparations - prevention and treatment of iron deficiency anemia.
גרדסיל 9
merck sharp & dohme (israel - 1996) company ltd, israel - hpv type 11 l1 protein; hpv type 16 l1 protein; hpv type 18 l1 protein; hpv type 31 l1 protein; hpv type 33 l1 protein; hpv type 45 l1 protein; hpv type 52 l1 protein; hpv type 58 l1 protein; hpv type 6 l1 protein - תרחיף להזרקה - hpv type 58 l1 protein 20 mcg / 0.5 ml; hpv type 52 l1 protein 20 mcg / 0.5 ml; hpv type 45 l1 protein 20 mcg / 0.5 ml; hpv type 33 l1 protein 20 mcg / 0.5 ml; hpv type 31 l1 protein 20 mcg / 0.5 ml; hpv type 18 l1 protein 40 mcg / 0.5 ml; hpv type 16 l1 protein 60 mcg / 0.5 ml; hpv type 11 l1 protein 40 mcg / 0.5 ml; hpv type 6 l1 protein 30 mcg / 0.5 ml - papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58)
קיילינה
bayer israel ltd - levonorgestrel - levonorgestrel 19.5 mg - levonorgestrel
קיילינה
bayer israel ltd - levonorgestrel - levonorgestrel 19.5 mg - levonorgestrel
רווהכול
megapharm ltd - borneol; camphene; cineole; menthol; menthone; pinene; pinene - קפסולות - menthol 32 mg; menthone 6 mg; pinene 3.4 mg; borneol 5 mg; camphene 5 mg; cineole 2 mg; pinene 13.6 mg
רייאטאז 300 מג
bristol - myers squibb, israel - atazanavir as sulfate - קפסולות - atazanavir as sulfate 300 mg - atazanavir
נובוסבן אר.טי 1 מג בקבוקון
novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 1 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.
נובוסבן אר.טי 2 מג בקבוקון
novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 2 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.